In November 2026, a large part of the hemp-derived intoxicant market disappears. H.R. 5371—the Hemp and Hemp-Derived Products Regulation Act—passed the House in early 2026 and closes what regulators call the “intoxicant loophole” that made delta-8 THC, HHC, delta-10, and related cannabinoids legal to sell nationwide.
If you’ve been buying hemp-derived gummies for their psychoactive effects, your options are about to narrow.
Amanita muscaria gummies are not affected. Here’s why, and what it means for anyone in this space.
What H.R. 5371 actually does
The short version: H.R. 5371 restricts psychoactive hemp-derived cannabinoids that aren’t delta-9 THC, CBD, or CBG. The synthetic conversion process that made delta-8 and HHC commercially viable—converting CBD into intoxicating compounds—would be federally prohibited.
The enforcement date is November 1, 2026. After that, products like delta-8 THC gummies, HHC gummies, THCO, delta-10, and THCp would be either prescription-controlled or federally illegal in most formulations currently sold online and in stores.
The hemp industry has estimated this will remove billions of dollars in annual revenue from the market. TRÉ House, Erth Wellness, Koi, and dozens of other brands with large delta-8 or HHC product lines face major cuts. Some will pivot to delta-9 THC gummies (legal in hemp-compliant doses below 0.3% by dry weight), or to CBD-only products. But the intoxicant segment—the products people buy because they actually do something—is largely going away at the federal level.
Amanita muscaria is chemically unrelated
Amanita muscaria gummies don’t contain cannabinoids. The active compound is muscimol, a GABA-A receptor agonist with zero structural or pharmacological relationship to THC, CBD, or any hemp-derived compound.
Muscimol is not scheduled under the DEA’s Controlled Substances Act. It’s not addressed in H.R. 5371. The FDA’s December 2024 statement on amanita muscaria products focused on labeling and safety standards, not prohibition.
The legal status is different not because of a technicality. Muscimol operates on a completely different mechanism in a completely different regulatory category. Hemp legislation applies to Cannabis sativa L. and its derivatives. Amanita muscaria is a mushroom. The two are unrelated at every level: botanical, chemical, and regulatory.
What this means if you’re shopping for legal alternatives
The most common question after H.R. 5371 passed: “Okay, if delta-8 is gone, what’s left?”
A few categories remain:
Delta-9 THC gummies—legal in hemp-compliant doses (under 0.3% delta-9 by dry weight). Still available federally, but the doses are modest and brands in this space were already operating before H.R. 5371.
Amanita muscaria gummies—federally legal, regulated by FDA safety standards rather than DEA scheduling, with sedating and dissociative effects rather than the euphoric high most people associate with THC.
Blue lotus, kava, and kanna products—botanical supplements with mood-affecting properties. Not cannabinoids. Not scheduled. No connection to hemp regulation.
CBD and CBG products—explicitly carved out in H.R. 5371. Non-intoxicating cannabinoids stay legal.
Amanita gummies and hemp-derived THC gummies have overlapping consumer interest but very different effect profiles. People who bought delta-8 for a clean, social, slightly euphoric experience may find amanita’s sedating, introspective effects aren’t a direct substitute. What they share is legal access and a pharmacological mechanism that has nothing to do with psilocybin.
Where Wunder stands
Wunder has never sold hemp-derived THC products. The lineup—amanita muscaria gummies, kava, blue lotus, and kanna—is built around botanical compounds that operate outside the cannabinoid system.
That wasn’t accidental. H.R. 5371 has been in regulatory discussions since 2022. Building around non-cannabinoid mechanisms was partly a compliance call and partly a product philosophy: effects from plants with long histories of documented human use, not from synthetic conversion processes.
The amanita muscaria space has its own regulatory questions. The FDA’s December 2024 alert focused on standardization: accurate muscimol content labeling and low residual ibotenic acid. That’s the standard Wunder was built to meet.
For the broader question—what’s left in the legal botanical market after November 2026—amanita gummies, kava, blue lotus, and kanna are among the few categories where the rules aren’t changing.
What to watch between now and November 2026
State actions. Some states have already moved faster than the federal timeline. Louisiana, Colorado, and Oregon have existing restrictions on intoxicating hemp derivatives. A few states have enacted or proposed amanita-specific rules too. State law can cut either way.
Senate timeline. H.R. 5371 passed the House but still needs Senate action and presidential signature. The schedule could slip. Most industry planning treats November 2026 as the date, though it’s not locked in.
FDA’s amanita framework. If the FDA moves toward formal amanita regulations, it would likely raise the floor for product quality. Brands already meeting pharmaceutical-grade testing standards would benefit. Brands relying on loose labeling won’t.
The practical takeaway
If you’ve been buying delta-8, HHC, or THCO products, expect your options to shrink by late 2026. Some brands will survive by pivoting. Most won’t.
If you’re curious about amanita muscaria, kava, or blue lotus gummies, the period where these are among the few legal botanical options for psychoactive experiences is getting longer, not shorter.
Wunder’s current lineup: Shop Wunder.
For more on how amanita muscaria works, what muscimol does, and state-by-state legal status: Amanita muscaria guide, muscimol gummies explainer, mushroom gummies legal guide.
Last updated: May 2026. H.R. 5371 status: passed House, pending Senate.
